title: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature.
abstract: BACKGROUND
  Gastrointestinal tract small cell carcinoma is an infrequent and aggressive neoplasm that represents 0.1-1% of gastrointestinal malignancies. Very few cases of small cell esophageal carcinoma arising in Barrett's esophagus have been reported in the literature. An extremely rare case of primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus is herein presented.
  
  
  METHODS
  A 62-year-old man with gastroesophageal reflux history presented with epigastric pain, epigastric fullness, dysphagia, anorexia, and weight loss. Esophagogastroscopy revealed an ulceroproliferative, intraluminar mass in the distal esophagus obstructing the esophageal lumen. Biopsy showed small cell esophageal carcinoma. Contrast-enhanced chest and abdominal computed tomography demonstrated a large tumor of the distal third of the esophagus without any lymphadenopathy or distant metastasis. Preoperative chemotherapy with cisplatine and etoposide for 3 months resulted in a significant reduction of the tumor. After en block esophagectomy with two field lymph node dissection, proximal gastrectomy, and cervical esophagogastric anastomosis, the patient was discharged on the 14th postoperative day. Histopathology revealed a primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus. The patient received another 3 month course of postoperative chemotherapy with the same agents and remained free of disease at 12 month review.
  
  
  CONCLUSIONS
  Although small cell esophageal carcinoma is rare and its association with dysplastic Barrett's esophagus is extremely infrequent, the high carcinogenic risk of Barrett's epithelium should be kept in mind. Prognosis is quite unfavorable; a better prognosis might be possible with early diagnosis and treatment strategies incorporating chemotherapy along with oncological radical surgery and/or radiotherapy as part of a multimodality approach. Since treatment protocols are not well established due to the rarity of the neoplasm, multi-institutional studies are needed to obtain sufficiently large populations for investigation and optimization of therapy of the disease.
authors.affiliation: Department of Propaedeutic Surgery, Hippokrateion Hospital, Athens Medical School, University of Athens, Athens, Greece. markogiannakis@easy.com
authors.forename: Haridimos
authors.initials: H
authors.lastname: Markogiannakis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Theodorou
authors.forename: Konstantinos G
authors.initials: KG
authors.lastname: Toutouzas
authors.forename: Andreas
authors.initials: A
authors.lastname: Larentzakis
authors.forename: Michael
authors.initials: M
authors.lastname: Pattas
authors.forename: Angeliki
authors.initials: A
authors.lastname: Bousiotou
authors.forename: Pavlos
authors.initials: P
authors.lastname: Papacostas
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Filis
authors.forename: Stilianos
authors.initials: S
authors.lastname: Katsaragakis